Keywords: fda, approves, bw, lamictal, wellcome, subsidiary, burroughs
FDA Approves BW's Lamictal
Article | 09 January 1995
Wellcome's US subsidiary, Burroughs Wellcome, has received approval from the US Food and Drug Administration to market Lamictal (lamotrigine), its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
